

## Baloxavir vs Favipiravir for COVID-19

**Author(s):** Cruciani F, De Crescenzo F, Vecchi S, Saulle R, Mitrova Z, Amato L, Davoli M.

**Question:** Should Baloxavir vs Favipiravir be used for COVID-19?

**Setting:** Inpatient

Certainty assessment							№ of patients		Effect		Certainty
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Baloxavir	Favipiravir	Relative (95% CI)	Absolute (95% CI)	
<b>SARS-CoV-2 clearance</b>											
1 <sup>1,a</sup>	randomised trials	very serious <sup>b</sup>	not serious	not serious	very serious <sup>c</sup>	none	7/10 (70.0%)	7/9 (77.8%)	<b>RR 0.90</b> (0.53 to 1.54)	<b>78 fewer per 1.000</b> (from 366 fewer to 420 more)	⊕○○○ VERY LOW
<b>Number of patients with respiratory failure and respiratory distress syndrome</b>											
1 <sup>1</sup>	randomised trials	very serious <sup>b</sup>	not serious	not serious	very serious <sup>c</sup>	none	6/10 (60.0%)	4/9 (44.4%)	<b>RR 1.35</b> (0.56 to 3.28)	<b>156 more per 1.000</b> (from 196 fewer to 1.000 more)	⊕○○○ VERY LOW
<b>Mortality any cause</b>											
1 <sup>1</sup>	randomised trials	very serious <sup>b</sup>	not serious	not serious	serious <sup>d</sup>	none					⊕○○○ VERY LOW

**CI:** Confidence interval; **RR:** Risk ratio

Explanations

- a. Both groups receive standard treatment involving Lopinavir / Ritonavir or darunavir / cobicistat and umifenovir, in combination with interferon  $\alpha$
- b. Downgraded of two levels for selection bias and attrition bias
- c. Downgraded of two levels for very low number of events and very small sample size
- d. Downgraded of one level for small sample size

### References

1. Lou Y, Liu L, Yao H, et al. Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial. medRxiv doi: <https://doi.org/10.1101/2020.04.29.20085761>